Insulet (PODD) Share-based Compensation Growth (1y) (2011 - 2026)
Insulet (PODD) Share-based Compensation Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 9.69% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 37.62% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 6.74% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 12.16% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | 12.94% |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | - |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 59.09% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | -30.44% |
| 10 | Insulet | 11.52 Bn | 11.04 Bn | 529.10 Mn | -25.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.94% |
| Dec 31, 2025 | -98.84% |
| Sep 30, 2025 | 107.12% |
| Jun 30, 2025 | -93.51% |
| Mar 31, 2025 | 324.00% |
| Dec 31, 2024 | 406.67% |
| Sep 30, 2024 | -235.53% |
| Jun 30, 2024 | 1,646.67% |
| Mar 31, 2024 | -56.14% |
| Dec 31, 2023 | -300.89% |
| Sep 30, 2023 | 153.33% |
| Jun 30, 2023 | -72.22% |
| Mar 31, 2023 | -25.49% |
| Dec 31, 2022 | -59.57% |
| Jun 30, 2022 | 121.09% |
| Mar 31, 2022 | -41.38% |
| Dec 31, 2021 | 855.17% |
| Jun 30, 2021 | -235.45% |
| Mar 31, 2021 | 230.38% |
| Dec 31, 2020 | 123.97% |